Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first half of 2025, showing a revenue increase of 11.02% and a net profit rise of 10.74% compared to the previous year. The financial performance indicates a stable growth trajectory, with improvements in net cash flow from operating activities and earnings per share, reflecting positively on the company’s operational efficiency and market positioning.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a company involved in the pharmaceutical industry, with a focus on the production and distribution of pharmaceutical products. The company holds a significant stake in Dong-E-E-Jiao, a subsidiary listed on the Shenzhen Stock Exchange, which specializes in traditional Chinese medicine products.
Average Trading Volume: 11,891,732
Technical Sentiment Signal: Sell
Current Market Cap: HK$33.05B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.